Alithea Genomics specializes in advanced RNA sequencing technologies that facilitate high-throughput and high-content gene expression studies across various applications, including drug screening, biomarker discovery, fundamental research, and crop science. Their innovative approach allows for massive sample multiplexing, enabling up to 384 library preparations in a single tube. This is achieved through the use of highly optimized barcoded primers that uniquely tag individual RNA samples during the library preparation workflow, allowing for efficient pooling and processing. Additionally, Alithea's technologies eliminate the need for tedious RNA extraction steps by utilizing a specialized cell lysis buffer that enables direct library preparation from frozen cells, thus streamlining the workflow and reducing manual labor.

The company offers several proprietary technologies, including MERCURIUS™ and BRB-seq, which are designed for cost-effective and scalable bulk RNA sequencing. MERCURIUS™ provides a rapid, extraction-free method for generating sequencing-ready libraries, while BRB-seq allows for the sequencing of thousands of samples in a single experiment. These technologies are compatible with various sample types, from purified RNA to complex tissues, and support diverse sequencing options, including targeted and full-length RNA sequencing. Alithea Genomics emphasizes the reliability and accuracy of their results, which are comparable to gold-standard RNA-seq data, while also promoting sustainability through reduced reagent and plastic consumption in research processes.

Switzerland

Developing solutions that simplify and streamline the generation of "big RNA data", which we believe will constitute the foundation of tomorrow's research and medicine.

Alithea Genomics

Company Details